

Table of Contents

S. No.	Description	Page No.
a)	List of Figures	xiii
b)	List of Tables	xvi
c)	List of Abbreviations	xvii
d)	List of Symbols	xx
e)	Preface	xxii
1	Chapter 1: Introduction	1
1.1	Neurodegenerative disorders: Alzheimer's Disease (AD)	1
1.2	Stages of Alzheimer's Disease	2
1.3	Pathophysiology of AD	3
1.3.1	Cholinergic hypothesis	3
1.3.2	Amyloid beta (A β) hypothesis	4
1.3.3	Tau hypothesis	5
1.3.4	Inflammation	6
1.4	Diagnostic approaches for AD	6
1.4.1	Diagnostic markers	7
1.4.1.1	A β species	7
1.4.1.2	Hyperphosphorylated Tau peptide	8
1.5	Therapeutic drug targets in AD	9
1.5.1	Cholinesterase Inhibitors	9
1.5.2	A β Aggregation Inhibitors	10
1.5.3	BACE-1 Inhibitors	10
1.5.4	Tau Aggregation Inhibitors	10
1.5.5	Metal-induced protein aggregation inhibitors	11
1.6	Clinical drugs for the treatment of AD	11
2	Chapter 2: Literature review	13
2.1	Theranostics fluorescent probes	13
2.2	Fluorescent probes with classical push-pull architecture	13
2.3	Fluorescent probe designed with novel strategies	15
2.4	Multi-target directed ligands (MTDLs)	18
2.4.1	Rational Combination of Multiple Targets for MTDLs	19

2.4.2	Rational Design of MTDLs	20
2.4.3	MTDLs lead optimization	20
2.5	Computer-aided drug discovery	21
3	Chapter 3: Objectives, rationale and plan of work	23
3.1	Objective and rationale	23
3.2	Plan of work	24
4	Chapter 4: Development of multifunctional fluorescence-emitting potential theranostic agents	26
4.1	Design strategy	26
4.2	Experimental procedures	29
4.2.1	Chemistry	29
4.2.1.1	General procedure for the synthesis of 3 & 34-38	30
4.2.1.2	General procedure for the synthesis of 5 & (39-43)	32
4.2.1.3	General procedure for the synthesis of 6	35
4.2.1.4	General procedure for the synthesis of 18-28	36
4.2.2	<i>In-vitro</i> cholinesterase inhibition	42
4.2.3	<i>In-vitro</i> blood-brain barrier permeation assay	43
4.2.4	Measurement of photophysical properties	44
4.2.5	Binding studies with A β ₁₋₄₂ aggregates	44
4.2.6	<i>In vitro</i> saturation binding assay using A β ₁₋₄₂ aggregates	45
4.2.7	<i>In situ</i> fluorescence imaging of A β aggregation	45
4.2.8	Fluorescence lifetime measurement	46
4.2.9	Density functional theory (DFT) calculation	46
4.2.10	Molecular docking analysis	47
4.2.11	<i>In vivo</i> biological evaluations	47
4.2.11.1	Animals, housing, and ethical approval	47
4.2.11.2	Acute toxicity studies	47
4.2.11.3	Behavioural studies (Scopolamine-induced amnesia model)	48
4.2.11.4	<i>Ex-vivo</i> biochemical analysis	49
4.3	Results and discussions	50
4.3.1	Chemistry	50
4.3.2	<i>In-vitro</i> cholinesterase inhibition	51
4.3.3	<i>In-vitro</i> blood-brain barrier permeation assay	52

4.3.4	Measurement of photophysical properties	54
4.3.5	Binding studies with A β ₁₋₄₂ aggregates	55
4.3.6	<i>In vitro</i> saturation binding assay using A β ₁₋₄₂ aggregates	56
4.3.7	<i>In situ</i> fluorescence imaging of A β aggregation	56
4.3.8	Fluorescence lifetime measurement	57
4.3.9	Density functional theory (DFT) calculation	59
4.3.10	Molecular docking analysis	60
4.3.11	<i>In vivo</i> biological evaluations	63
4.3.11.1	Acute toxicity studies	63
4.3.11.2	Behavioural studies (Scopolamine-induced amnesia model)	63
4.3.11.3	<i>Ex-vivo</i> biochemical analysis	65
4.4	Summary and conclusion	66
5	Chapter 5: Development of donor-acceptor architecture-based theranostic fluorescent probes	68
5.1	Design strategy	68
5.2	Experimental procedures	71
5.2.1	Chemistry	71
5.2.1.1	General procedure for the synthesis of 6-9 & 21	72
5.2.1.2	General procedure for the synthesis of compounds 11-14; 16-19 & 22-23.	73
5.2.2	Measurement of photophysical properties	75
5.2.3	<i>In-vitro</i> cholinesterase inhibition	75
5.2.4	<i>In vitro</i> binding studies with A β ₁₋₄₂ aggregates	76
5.2.5	<i>In vitro</i> saturation binding assay using A β ₁₋₄₂ aggregates	77
5.2.6	A β deposit fluorescence imaging in the <i>Drosophila</i> AD model	77
5.2.6.1	Thioflavin T staining	78
5.2.6.2	Staining for Probe 18	78
5.2.7	<i>In vivo</i> biological evaluations	79
5.2.7.1	Animals, housing, and ethical approval	79
5.2.7.2	Acute oral toxicity studies	79
5.2.7.3	Behavioural studies (Scopolamine-induced amnesia model)	79
5.2.7.4	<i>Ex-vivo</i> biochemical analysis	81
5.3	Results and discussions	82

5.3.1	Chemistry	82
5.3.2	<i>In-vitro</i> cholinesterase inhibition	82
5.3.3	Measurement of photophysical properties	85
5.3.4	<i>In vitro</i> binding studies with A β ₁₋₄₂ aggregates	87
5.3.5	<i>In vitro</i> saturation binding assay using A β ₁₋₄₂ aggregates	88
5.3.6	A β deposit fluorescence imaging in the <i>Drosophila</i> AD model	89
5.3.7	<i>In vivo</i> biological evaluations	90
5.3.7.1	Acute oral toxicity studies	90
5.3.7.2	Behavioural studies (Scopolamine-induced amnesia model)	91
5.3.7.3	<i>Ex-vivo</i> biochemical analysis	93
5.4	Summary and conclusion	95
6	Chapter 6: Development of multi-targetable chalcone derivatives bearing <i>N</i>-aryl piperazine moiety	97
6.1	Design Strategy	97
6.2	Experimental procedures	99
6.2.1	Chemistry	99
6.2.1.1	General procedure for the synthesis of compounds 8–9 & 31	100
6.2.1.2	General procedure for synthesis of compounds 18–28; 38–43	102
6.2.2	Prediction of ADMET properties	112
6.2.3	<i>In-vitro</i> cholinesterase inhibition assay	112
6.2.4	<i>In-vitro</i> blood–brain barrier permeation assay	113
6.2.5	<i>h</i> BACE-1 inhibition assay	114
6.2.6	Self-induced and AChE-induced A β ₁₋₄₂ aggregation inhibition	114
6.2.7	Molecular docking	115
6.2.8	Molecular dynamics	116
6.2.9	<i>In vivo</i> biological evaluations	116
6.2.9.1	Animals, housing, and ethical approval	116
6.2.9.2	Acute oral toxicity studies	115
6.2.9.3	Behavioural studies (Scopolamine-induced amnesia model)	117
6.2.9.4	<i>Ex-vivo</i> biochemical analysis	118
6.3	Results and discussions	119
6.3.1	Chemistry	119
6.3.2	Prediction of ADMET properties	121

6.3.3	<i>In-vitro</i> cholinesterase inhibition	123
6.3.4	<i>In-vitro</i> blood–brain barrier permeation assay	124
6.3.5	<i>h</i> BACE-1 inhibition assay	126
6.3.6	Self-induced and AChE-induced A β ₁₋₄₂ aggregation inhibition	126
6.3.7	Molecular docking analysis	127
6.3.8	Molecular dynamics	129
6.3.9	<i>In vivo</i> biological evaluation	132
6.3.9.1	Acute oral toxicity studies	132
6.3.9.2	Behavioural studies (Scopolamine-induced amnesia model)	133
6.3.9.3	<i>Ex-vivo</i> biochemical analysis	134
6.4	Summary and conclusion	135
7	Chapter 7: Discovery of pyrazoline analogs through lead optimization strategy	137
7.1	Design Strategy	137
7.2	Experimental procedures	139
7.2.1.	Chemistry	139
7.2.1.1	General procedure for synthesis of compounds 4 – 5	140
7.2.1.2	General procedure for synthesis of compounds 16 – 31	140
7.2.1.3	General procedure for synthesis of compounds 32 – 47	140
7.2.1.4	General procedure for synthesis of compounds 48 – 57	145
7.2.2	<i>In-vitro</i> cholinesterase inhibition assay	148
7.2.3	<i>In-vitro</i> blood-brain barrier permeation assay	149
7.2.4	<i>h</i> BACE-1 inhibition assay	149
7.2.5	Self-induced and AChE-induced A β ₁₋₄₂ aggregation inhibition	150
7.2.6	Molecular docking	150
7.2.7	Molecular dynamics	151
7.2.8	<i>In vivo</i> biological evaluations	152
7.2.8.1	Animals, housing, and ethical approval	152
7.2.8.2	Acute oral toxicity studies	152
7.2.8.3	Behavioural studies (Scopolamine-induced amnesia model)	152
7.2.8.4	<i>Ex-vivo</i> biochemical analysis	154
7.3	Results and discussion	155
7.3.1	Chemistry	155

7.3.2	<i>In-vitro</i> cholinesterase inhibition	156
7.3.3	<i>In-vitro</i> blood-brain barrier permeation assay	159
7.3.4	<i>h</i> BACE-1 inhibition assay	159
7.3.5	Self-induced and AChE-induced A β ₁₋₄₂ aggregation	160
7.3.6	Molecular docking analysis	161
7.3.7	Molecular dynamics	164
7.3.8	<i>In vivo</i> biological evaluations	166
7.3.8.1	Acute oral toxicity studies	166
7.3.8.2	Behavioural studies (Scopolamine-induced amnesia model)	166
7.3.8.3	<i>Ex-vivo</i> biochemical analysis	167
7.4	Summary and conclusion	169
8	Chapter 8: Summery and conclusions	171
9	Chapter 9: References	176
10	Appendix	190